the potential to change standard practice
Woburn, MA (PRWEB) October 9, 2008
Pluromed, Inc., a private medical device company that is pioneering clampless vascular and cardiovascular surgery, is delighted to announce that it has been awarded the prestigious 2008 EACTS Techno-College Innovation Award for its LeGoo Internal Vessel Occluder. The award was established by the European Association of Cardio-Thoracic Surgery (EACTS) to recognize the most important technological breakthrough in any area related to thoracic and cardiovascular surgery, a breakthrough that has "the potential to change standard practice". The award was announced at the Annual Techno-College meeting in Lisbon on September 13th in front of an audience of over 1,200 leading cardiovascular and thoracic surgeons from around the world.
LeGoo™ is approved for human use in Europe and is already in clinical use in some of the leading clinical centers of France, Germany, The Netherlands, Spain and Switzerland. The first clinical applications include off-pump and on-pump coronary artery bypass surgery, femoral bypass, arteriovenous fistula for hemodialysis patients and procedures involving the temporary occlusion of large arteries.
Pluromed CEO Jean-Marie Vogel, who received the award for Pluromed, summarized in his acceptance speech the feedback he is getting from surgeons using LeGoo™ in their clinical practice: "For years, surgeons have been looking for a simpler, atraumatic method to control bleeding during surgery, but it simply didn't exist... Now, with LeGoo, surgeons can 'clamp' without a clamp, using a phase-changing liquid/gel. No more squeezing and pressurizing, and thus no more fear of damaging fragile or calcified blood vessels. LeGoo™ has the potential to revolutionize the practice of surgery."
LeGoo is indeed a revolutionary product with the potential to change the standard practice of surgery:
- Current techniques for controlling bleeding include the use of mechanical devices, such as clamps or vessel loops, which act by applying radial pressure to the vessel. That is a problem: they are often ineffective and can cause trauma or damage to the vessel. This problem is not a rare occurrence; it affects the majority of vascular surgeries, especially in older or diabetic patients.
- LeGoo is very different, and works like a "magic plug". With LeGoo surgeons can 'clamp' without clamping, thus controlling bleeding without fear of damaging fragile or calcified vessels, and perform needed procedures that might otherwise have been impossible. LeGoo exists as a liquid at lower temperatures but rapidly changes to a viscous gel at body temperature. When injected into a blood vessel, it forms a temporary plug that provides a bloodless field for the duration of the vascular procedure. At the end the surgeon "removes" the plug by touching the vessel with ice, which dissolves the plug.
"This is a tremendous moment for Pluromed," Vogel added. "The response from surgeons, who have already used LeGoo or who have just recently been exposed to it via this award, has been outstanding. We look forward to continuing our market launch internationally and to progressing towards FDA approval."
The market for LeGoo includes over 2,000,000 procedures a year in elder and diabetic patients with fragile arteries.
About Pluromed, Inc.:
Pluromed, Inc., Woburn, Massachusetts, founded in 2003, is a commercial stage company pioneering the use of injectable plugs to improve the safety, efficacy and economics of medical interventions. These products address a broad surgery market that includes cardiac and vascular surgery, prostate, kidney and liver surgery, plastic/reconstructive surgery, trauma/battlefield applications and the treatment of kidney stones. They are based on the Company's patented rapid reverse thermosensitive polymer technology; the polymers are liquid at low temperature and quickly transition to a high viscosity gel at body temperature.
The European Association of Cardio-Thoracic Surgery was founded in 1986. Its 2000 members are spread all over the world in all continents, representing some 70 countries. The main objects of the EACTS are to advance education in the field of cardiovascular and thoracic surgery, and to promote for the public benefit research in thoracic physiology, pathology and therapy and to correlate and disseminate the useful results thereof.
Certain statements made in this press release may be considered to be "forward-looking statements". Such forward-looking statements represent the expectations or beliefs of the management of Pluromed, Inc. concerning future events and include, without limitation, statements containing the words "believes", "plans"," anticipates", "expects", "may" and words of similar meaning or import. Such forward-looking statements relate to potential future events and the potential future financial performance of Pluromed, Inc. and the industry in which it is involved and the economic and political condition of the countries in which Pluromed, Inc. does or plans to do business and involve known and unknown risks, uncertainties and other important factors which could cause actual results, performance or achievements to differ materially from the results predicted in any forward looking statement. These forward-looking statements should not be relied upon as representing Pluromed's expectations or beliefs as of any date subsequent to the date of this press release.
Jean-Marie Vogel, Chief Executive Officer
Source: Pluromed Inc.